Gold Standard Diagnostics, a Eurofins Technologies Company, Launches CE Marked Assay for the Detection of the Omicron SARS-CoV-2 Variant
Gold Standard Diagnostics continues its response to the threat of the emerging Omicron SARS-CoV-2 variant by providing innovative diagnostic solutions.
The Omicron SARS-CoV-2 variant has raised significant concerns given its rapid spread in South Africa and has now been confirmed in over 40 countries. The variant contains many mutations which may enable the virus to evade the immune response raised by previous infection or vaccination.
With the current uncertainty surrounding the dangers of the Omicron SARS-CoV-2 variant, it is crucial to closely monitor its spread and provide reliable diagnostic solutions for its identification. By now, the variant has already split in two sublineages (BA.1 & BA.2) one of which, nicknamed the ‘stealth Omicron’, does not carry the Spike protein deletion 69/70. This deletion, however, has so far been used as a workaround to identify this variant through a dropout in a widely used RT-PCR assay .
Gold Standard Diagnostics Europe now offers a rapid and reliable RT-PCR assay detecting Omicron SARS-CoV-2 variant, including both sublineages. GSD NovaType II SARS-CoV-2 specifically identifies mutations N501Y and K417N, present in Omicron in approximately 1 hour, much faster than genome sequencing methods. The assay is CE-marked and available immediately.
GSD NovaType II SARS-CoV-2 supplements the product range developed in response to emerging SARS-CoV-2 variants, such as GSD NovaType Detect & Select K417N SARS-CoV-2 (RUO), that combines SARS-CoV-2 detection and identification of an Omicron signature mutation in one reaction.
For more information, please visit Eurofins Technologies website.
About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods
Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast-growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For further information:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ferring Receives U.S. FDA Approval for REBYOTA ® (fecal microbiota, live-jslm) – A Novel First-in-Class Microbiota-Based Live Biotherapeutic1.12.2022 01:53:00 CET | Press release
Ferring Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approved REBYOTA® (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130006155/en/ “Until now, patients living with the devastating cycle of recurrent C. difficile infection have had limited FDA-approved treatment options, causing them to suffer long periods of time with debilitating symptoms that prevent them from leaving their homes and even separate them from immediate family members,” said Paul Feuerstadt, M.D., F.A.C.G., A.G.A.F., Yale University School of Medicine. “REBYOTA is a much-needed new treatment that offers hope to the thousands of people who suffer from recurrent
ViiV Healthcare Unveils a New Global Study Revealing Three Quarters of People Believe There Are Still Negative Perceptions When It Comes to People Living With HIV1.12.2022 01:01:00 CET | Press release
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from a perceptions survey which unveils a widespread gap in public knowledge and understanding of HIV worldwide. The data found that three quarters of people (74%) believe that there are still negative perceptions when it comes to people living with HIV, and that one in six adults agree that if a friend or colleague was living with HIV, they might look at them negatively. While the majority of people surveyed did report feeling comfortable with physical contact, including holding hands (76%) or hugging (75%), only 1 in 2 people would feel comfortable dating someone living with HIV. Concerningly, the survey also found that a quarter of adults (25%) believe that it is not appropriate for employees to talk about HIV in the workplace, a factor continuing to perpetuate HIV as a taboo subject.1 The survey, conducted online by Opinium in 2022, collected
IFF Names Dennis Maroney Master Perfumer30.11.2022 22:20:00 CET | Press release
IFF (NYSE: IFF) has named Dennis Maroney Master Perfumer, an honor recognizing his career achievements, entrepreneurial contributions and record of commercial excellence in the global perfumery industry. Maroney is a 32-year industry veteran and IFF’s ninth Master Perfumer, a distinction reserved for those who have demonstrated exceptional leadership and measurable impact in perfumery. “Dennis has demonstrated a unique ability to bring together science and creativity, with a strong, undefeatable sense of purpose,” said Frank Clyburn, CEO, IFF. “He is a humble leader and an inspiring mentor who has created milestone scent signatures in the beauty and home care world. His unique contributions to the products we use every day in our beauty and home care routines are truly inspiring, and this Master Perfumer recognition is more than deserved.” Commenting on his Master Perfumer appointment, Maroney said: “Perfumery is about transporting the consumer to a time and place where they are happy.
Digital Integrator Cohesive Group Acquires Vetasi, Leading Provider of IBM Maximo Managed Services30.11.2022 22:03:00 CET | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that its Cohesive Group digital integrator business has acquired Vetasi, a leading international consultancy specializing in enterprise asset management (EAM) solutions, with a strong focus on IBM Maximo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130006068/en/ Image courtesy - Getty Images Vetasi brings to Cohesive the largest IBM Maximo consultancy team across Europe, Africa, and ASEAN countries, with headquarters in the United Kingdom and operations based in Poland, Indonesia, South Africa, Spain, Ukraine, and Australia. In addition to EAM resources, Vetasi deepens the Cohesive team with additional strategic advisory capabilities and adds to the Cohesive services catalog Maximo cloud hosting capabilities, expertise in low-code development, and strong real estate and facilities management domain knowledge. B
Everest Group Recognizes SoftServe as a Key Player in Digital Services within the Life Sciences Landscape30.11.2022 18:47:00 CET | Press release
SoftServe, a leader in digital services and consulting, has been recognized as an Aspirant in Everest Group's Life Sciences Digital Services PEAK Matrix® Assessment 2022. Everest Group is a provider of strategic research insights on IT, business processes, and engineering services and a global Business Process Outsourcing (BPO) research firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005890/en/ Everest Group Recognizes SoftServe as a Key Player in Digital Services within the Life Sciences Landscape (Graphic: Business Wire) The Life Sciences Digital Services PEAK Matrix® Assessment 2022 covers the top digital life sciences service providers, best-in-class solutions and products, and top locations, according to Everest Group's research. This is the first time SoftServe has been named in the Life Sciences sector. SoftServe debuted with an impressive score in Everest Group's two assessment areas: vision and strategy a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom